← All trials
NCT05690425
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 6, 2023
- Primary completion
- Mar 15, 2024
- Completion date
- Jun 15, 2024
- First posted
- Jan 19, 2023
- Last posted
- Jul 24, 2023
- Enrollment
- 13
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Biocity Biopharmaceutics Co., Ltd.Lead sponsor
- Jinan UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.